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Objectives: This meta-analysis was conducted to evaluate the impact of 
perioperative use of BB on POAF after cardiac surgery other than isolated 
CABG.  
Methods: Five online databases were searched. Studies were included if 
they (1) enrolled patients who underwent cardiac surgery other than isolated 
CABG and (2) demonstrated the impact of perioperative use of BB on POAF 
based on the randomized controlled trial or adjusted analysis. The primary 
outcome was the occurrence rates of POAF after cardiac surgery. A meta-
regression and Subgroup analysis were performed according to the 
proportion of patients with cardiac surgery other than isolated CABG and the 
timing of BB use, respectively. 
Results: Thirteen articles (5 randomized and 8 non-randomized studies: 
n=24,101) were selected. Proportion of enrolled patients undergoing cardiac 
surgery other than isolated CABG ranged from 7% to 100%. The BBs were 
used in preoperative, postoperative and both periods in 5, 5 and 3 studies, 
respectively. The pooled analyses showed that the risk of POAF was 
significantly lower in patients with perioperative BB than those without (odds 
ratio, 95% confidence interval=0.67, 0.54-0.83). Further analyses 
demonstrated that the risk of POAF was lower in the BB group irrespective 
of the proportion of non-isolated CABG and the timing of administration. In-
hospital mortality was reduced by 50% in BB group (OR, 95% CI=0.50, 0.32-
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0.79). Perioperative stroke and LOS were not significantly different between 
BB and non-BB groups.  
Conclusions: Perioperative use of BB is effective in preventing POAF even 
in patients undergoing cardiac surgery other than isolated CABG.  
 
Keywords: Cardiac Surgery, Atrial Fibrillation, Beta-Blocker 








List of Tables and Figures……………………………………………..v  
L ist  of  Abbreviat ions…………………………………………… . .v i 
 
1. Introduction  ......................................................................................... 1 
2. Materials and Methods ......................................................................... 2 
 2.1. Data source & literature search....................................................... 2 
 2.2. Study selection ................................................................................. 3 
2.3. Data extraction ................................................................................. 3 
2.4. Assessment quality .......................................................................... 3 
2.5. Statistical Analysis ........................................................................... 4 
3. Results ................................................................................................... 6 
 3.1. Identification of studies ................................................................... 6 
3.2. Study characteristics and patient populations .............................. 6 
3.3. Quality of the included studies ....................................................... 7 
3.4. Primary outcomes ............................................................................ 7 
iv 
 
3.5. Secondary outcomes ....................................................................... 8 
3.6. Publication bias .............................................................................. 10 
 
Discussion .............................................................................................. 11 
Study limitatoins ..................................................................................... 13 
Conclusion .............................................................................................. 13 
 
References .............................................................................................. 14 




LIST OF TABLES AND FIGURES 
 
Table 1 Study characterist ics.…………………… .…… . .……… . .19 
Table 2 Patients characteristics………………………………………..21 
Table 3 Quality assessment of included studies………………………..23 
Figure 1 ……………………………………………………………………..24 
Figure 2 ……………………………………………………………………..25 
Figure 3 ……………………………………………………………………..26 
Figure 4 ……………………………………………………………………..27 
Figure 5 ……………………………………………………………………..28 
Figure 6 ……………………………………………………………………..29 
Figure 7 ……………………………………………………………………..30 
Figure 8 ……………………………………………………………………..31 
Figure 9 ……………………………………………………………………..32 




LIST OF ABBREVIATIONS 
AF = atrial fibrillation 
BB = beta-blocker 
CABG = coronary artery bypass graft surgery 
CI = confidence interval 
LOS = length of stay 
MD = mean difference 
MeSH = medical subject heading  
NRS = non-randomized study 
OR = odds ratio  
POAF = postoperative atrial fibrillation 
PRISMA = Preferred Reporting Items for Systematic reviews and 
Meta-analyses 
RCT = randomized controlled trial 
ROB = risk of bias 







Atrial fibrillation (AF) is one of the most common complications after cardiac 
surgery. Although it resolves spontaneously in most patients, postoperative 
AF (POAF) after cardiac surgery is associated with significant mortality and 
morbidity, including prolonged ventilator support, renal failure and stroke [1, 
2]. Many studies have evaluated the effect of different pharmacologic and 
non-pharmacologic interventions to prevent POAF after cardiac surgery, and 
current European guidelines recommend perioperative use of beta-blockers 
(BB) in patients undergoing cardiac surgery to prevent POAF [3]. However, 
evidences for this recommendation are mostly from studies exclusively 
enrolling patients undergoing coronary artery bypass graft surgery (CABG) 
[4] and current American guidelines recommend the use of perioperative BB 
to prevent POAF only for patients undergoing CABG [5]. 
Therefore, this meta-analysis was conducted to evaluate the impact of 
perioperative use of BB on the occurrence of POAF after cardiac surgery 
other than isolated CABG.  
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MATERIALS AND METHODS 
 
1. Data Source & Literature Search 
This systematic review and meta-analysis was conducted according to the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines [6]. Full-text articles evaluating the impact of 
perioperative use of BB on the incidence of POAF were searched for in the 
Medline, Embase, Cochrane Central Register of Controlled Trials, Web of 
Science and Scopus databases on September 21, 2018. No restrictions were 
placed on the language or publication year. 
The following keywords and medical subject heading (MeSH) terms were 
searched in Medline: ("adrenergic beta-antagonists"[MeSH Terms] OR 
"phenoxypropanolamines"[MeSH Terms] OR beta antagonist[Title/Abstract] 
OR beta blocker[Title/Abstract] OR metoprolol[Title/Abstract] OR 
propranolol[Title/Abstract] OR esmolol[Title/Abstract] OR 
timolol[Title/Abstract] OR atenolol[Title/Abstract] OR bisoprolol[Title/Abstract] 
OR acebutolol[Title/Abstract] OR nadolol[Title/Abstract] OR 
nebivolol[Title/Abstract] OR labetalol[Title/Abstract] OR 
carvedilol[Title/Abstract]) AND ("cardiac surgical procedures"[MeSH Terms] 
OR "heart valve prosthesis implantation"[MeSH Terms] OR 
surgery[Title/Abstract] OR surgical[Title/Abstract]) AND ("arrhythmias, 
cardiac"[MeSH Terms] OR atrial fibrillation[Title/Abstract]) OR 
arrhythmia[Title/Abstract]) OR tachycardia[Title/Abstract]). The search 
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strategies for other databases were adapted from this strategy. 
 
2. Study Selection  
Study selection was independently performed by two reviewers based on the 
selection criteria. Any disagreements between the reviewers were resolved 
through discussion. The study selection was conducted following two levels 
of screening: the titles and abstracts of the searched studies were screened 
at the first level and the full texts were reviewed at the second level.  
Studies were included if they met the following criteria: (1) studies enrolled 
patients who underwent cardiac surgery but not exclusively CABG and (2) 
studies analyzed the impact of perioperative use of BB on the incidence of 
POAF. When duplicated publications with overlapping study populations 
were found, the most appropriate article for the present study was selected. 
 
3. Data Extraction 
The study characteristics and the patients' baseline data were extracted 
independently by two reviewers. Data regarding study outcomes were also 
independently extracted by two reviewers. Any disagreements between the 
two reviewers were resolved through discussion. 
 
4. Assessment of Quality  
The overall study quality was assessed independently by two reviewers 
using the Cochrane Risk of Bias Tool for randomized controlled trials (RCTs) 
and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-
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I) for non-randomized studies (NRSs) [7]. In the ROBINS-I, seven domains 
of risk of bias (ROB) were assessed and the overall ROB was determined to 
be low, moderate, serious or critical based on the assessment of each 
domain. Any disagreements between the reviewers were resolved through 
discussion. 
 
5. Statistical Analysis 
The primary outcome was the incidence of POAF. Secondary outcomes 
included in-hospital mortality, postoperative stroke, length of stay (LOS) and 
complications related to the use of BB such as bradycardia, hypotension, 
permanent pacemaker insertion and reduction in BB dose.  
Dichotomous outcomes were compared as odds ratios (ORs) with the 95% 
confidence interval (CI). For a continuous outcome, results were presented 
as mean difference (MD) with 95% CI. For studies that reported median and 
interquartile values, the mean values and standard deviations were 
estimated using a formula [8]. For studies reporting results through both 
multivariable regression and propensity-score matching analyses, 
propensity-score matching estimates were selected for the present analyses. 
Statistical heterogeneity between the studies was assessed with the χ2 test 
and the I2 statistics. I2 values of 25%, 50% and 75% have been suggested to 
be indicators of low, moderate and high heterogeneities, respectively [9]. A 
random-effects model with the DerSimonian and Laird method was used if 
substantial heterogeneity was found (I2 >50%); otherwise, a fixed-effects 
model was applied using the Mantel–Haenszel and inverse variance 
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methods for binary outcomes with count data and the other outcomes, 
respectively. 
Pooled estimates from RCTs and NRSs, and overall pooled estimates were 
presented. The impact of the use of BB on the primary outcome according to 
the proportion of surgery other than isolated CABG was evaluated with a 
univariate meta-regression analysis. A subgroup analysis was performed for 
the primary outcome to identify the influences of timing of BB use 
(preoperative vs. intra- or postoperative vs. both pre- and postoperative use). 
Heterogeneity between subgroups was assessed using the Cochran’s Q test. 
For BB dose reduction in the BB group, the pooled proportion estimate was 
calculated using the Freeman-Tukey double arcsine transformation [10]. A 
funnel plot and Egger’s test for asymmetry were applied to assess the 
possibility of publication bias among the studies for the primary outcome and 
not for the secondary outcomes because of the small number of studies 
included [11].  
All analyses were performed using R version 3.5.1 (meta package). Two-






1. Identification of Studies 
The database searches found 10,206 articles. Among these, 10,179 
publications were excluded, because it was clear from the title and abstract 
that they did not fulfill the selection criteria. Full manuscripts of the remaining 
27 studies were reviewed. Nine publications were excluded because 
inclusion criteria were not met and a further three studies because of 
duplicated data. Another 2 studies were also excluded because only 
unadjusted results were demonstrated. Therefore, a total of 13 studies were 
included in this review (Figure 1) [12-24]. 
 
2. Study Characteristics and Patient Populations 
Among the 13 studies with 25,496 patients, 5 studies demonstrated the 
results of RCTs (n = 1,395), and 8 presented the outcomes of NRSs (n = 
24,101). Proportions of patients who underwent surgery other than isolated 
CABG ranged from 7% to 100%. The BB were used in the preoperative, intra- 
or postoperative, and both periods in 5, 5 and 3 studies, respectively. Types 
of BB evaluated were metoprolol, landilolol and mixed in 5, 2 and 1 studies, 
respectively. They were not described in the other 5 studies (Table 1). On an 
average, the patients were in their 60s and 70s, and 30% of the patients were 




3. Quality of the Included Studies 
The ROB of RCTs was graded as low, high or unclear. For the random 
number generation, 3 studies [13, 18, 22] were rated as low, whereas the 
other 2 studies [12, 19] were rated unclear. For blinding of participants and 
personnel domain, 2 studies [12, 13] were rated as low while the other 3 
studies were rated as high. The ROB of the 5 studies was considered low for 
the other 5 domains. All of the 8 NRSs were graded as having an overall 
moderate ROB because confounding variables were appropriately adjusted 
using multivariable models and matching in six [15-17, 20, 21, 24] and two 
[14, 23] studies, respectively. The other ROB items were graded as low 
(Table 3). 
 
4. Primary Outcomes 
4.1. Impact of the Use of Beta-Blockers on The 
Occurrence of POAF 
Pooled analyses from all of the included studies revealed that perioperative 
use of BB was associated with a 33% reduction of the occurrence of POAF 
(OR [95% CI] = 0.67 [0.54, 0.83], I2 = 76.8%, Figure 2). There was no 
significant difference between the OR from RCTs and that from NRSs (P 
= .414). 
 
4.2. Impact of the Use of Beta-Blockers According to the 
Proportion of Patients with Non-Isolated CABG 
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The meta-regression analysis revealed that the impact of the use of BB was 
not significantly affected by the proportion of patients with non-isolated 
CABG (P for trend = .611, Figure 3). 
 
4.3. Impact of the Use of Beta-Blockers According to the 
Timing of Administration 
The ORs for the use BB vs. non-use of BB was 0.80, 0.66 and 0.50 when 
they were used in preoperative, intra- or postoperative, and both pre- and 
postoperative periods, respectively. The Cochran’s Q test showed a 
marginally significant difference in the ORs according to the timing of 
administration (P = .088, Figure 4). 
 
5. Secondary Outcomes 
5.1. In-Hospital Mortality 
The In-hospital mortality was reported in 6 studies (4 RCTs and 2 NRSs) [12-
14, 19, 21, 22]. One [12] out of the 6 studies was excluded from subsequent 
pooled analyses because mortality rates were 0% in both groups, thus OR 
could not be calculated. In another study [23], a result comparing in-hospital 
mortality was presented only by univariate analysis and an adjusted OR was 
demonstrated for 90-day mortality. Pooled analysis of the former 5 studies 
with 4,115 patients demonstrated a significantly lower risk of in-hospital 
mortality in the BB group than in the non-BB group (OR [95% CI] = 0.50 [0.32, 
0.79], I2 = 15.6%, Figure 5). However, the pooled estimate was not 
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statistically significant when it was drawn from 7,612 patients after including 
the OR of 90-day mortality from the latter study (OR [95% CI] = 0.65 [0.38, 
1.12], I2 = 51%, Figure 5). 
 
5.2. Postoperative Stroke 
The risk of postoperative stroke was drawn from 5 studies (3 RCTs and 2 
NRSs with 6,344 patients [12-14, 22, 23]. The pooled analysis demonstrated 
that the risk of postoperative stroke was not significantly different between 
the BB and non-BB groups (OR [95% CI] = 0.89 [0.59, 1.35], I2 = 0%, Figure 
6). 
 
5.3. Length of Hospital Stay 
A pooled analysis from 6 studies [12-14, 19, 22, 23] with 6,492 patients 
showed that the LOS was not significantly different between the BB and non-
BB groups (MD [95% CI] = -0.22 [-0.70, 0.26] days, Figure 7). 
 
5.4. Events Associated with the Use of Beta-Blockers 
Postoperative events associated with the use of BB such as bradycardia, 
hypotension and permanent pacemaker insertion were reported in two [13, 
22], two [13, 22], and three [12, 13, 22] studies, respectively (Figure 8). The 
ORs for BB effect on bradycardia and hypotension were 6.06 (95% CI 1.27, 
28.88) and 0.20 (95% CI 0.01, 4.32), respectively based on one study [13]. 
The pooled OR on permanent pacemaker insertion was 1.02 (95% CI 0.20, 
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5.07). A pooled analysis from 4 studies [13, 18, 19, 22] showed that BB dose 
reduction was needed in 31% of patients in the BB group (Figure 9). 
 
6. Publication Bias 
Funnel plots and Egger's test for asymmetry suggested a publication bias for 






The present meta-analysis demonstrated that perioperative use of BB 
resulted in a 33% reduction in the occurrence of POAF after cardiac surgery 
other than isolated CABG.  
The incidence of POAF after cardiac surgery varies from 20% to 50%, 
depending on the definition, the methods of detection, and the specific types 
of surgery [3, 25-27]. The POAF usually develops within 2 to 4 postoperative 
days, with a peak incidence on the second postoperative day [28, 29]. 
Current European guidelines on the prevention of POAF after cardiac 
surgery issued perioperative administration of BB as a class I 
recommendation with a level of evidence A [3]. However, this 
recommendation was made based on a meta-analysis enrolling studies with 
mostly analyzed patients who underwent isolated CABG rather than other 
types of cardiac surgery [30]. This might be the reason that current American 
guidelines recommended the use of BB for prevention of POAF for CABG 
patients but not for overall cardiac surgery patients [5, 26]. A recently updated 
meta-analysis showed again the benefit of BB on the prevention of POAF 
after cardiac surgery [31]; the authors included 53 RCTs and demonstrated 
that the perioperative use of BB substantially reduced the occurrence of 
supraventricular arrhythmias by 56% (RR 0.44, 95% CI 0.36 to 0.53; p < 
0.001) after cardiac surgery. However, the analysis still enrolled studies 
mostly analyzing the benefit of the use of BB in isolated CABG patients; 45 
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out of the 53 studies were exclusively enrolled patients undergoing isolated 
CABG. The present meta-analysis was conducted because the evidence for 
the routine administration of perioperative BB to prevent POAF after cardiac 
surgery is still lacking for types of cardiac surgery other than isolated CABG. 
The pooled analysis demonstrated that the use of BB resulted in a 33% 
reduction of the risk of POAF after cardiac surgery. The meta-regression 
showed that the benefit of the use of BB was not significantly different among 
studies with different proportions of enrolled patients with non-isolated CABG.  
In the subgroup analysis, the timing of the use of BB showed no statistically 
significant differences regarding the protective effect on POAF. However, the 
OR was lowest when it was used at both pre- and postoperative periods than 
isolated preoperative or postoperative use only (ORs 0.50, 0.80 and 0.66, 
respectively, p = 0.088). This could be explained by possible adverse effects 
associated with a rebound phenomenon caused by discontinuation of the BB 
after surgery in patients who took them before surgery. This result is in 
accordance with current recommendations which described that patients 
who are already taking BB should continue to take them before and after 
surgery [32]. 
Although most episodes of POAF are transient and self-limiting in nature, 
they are significantly associated with mortality and morbidities including a 2 
to 4 times greater risk of stroke, heart failure, bleeding from anticoagulation, 
renal failure and prolonged ventilator care [1-3, 25-27, 29]. The results of the 
present study showing a 50% reduction of in-hospital mortality. However, this 
positive interpretation should be drawn carefully, because there was no 
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statistical significance when the pooled estimates included the OR of 90-day 
mortality in one more study [20]. In addition, the reduction of POAF did not 
translate into improvement of clinical outcomes such as a reduced 
occurrence of postoperative stroke or length of hospital stay. This might be 




There are several limitations to be noticed in this study. First, the studies 
included were not all RCTs, and confounding factors could affect the results 
of our analysis, although only adjusted results were included in the present 
study. Second, protocols regarding the use of BB such as the types of drugs 
and timing of the use varied between studies. Finally, a publication bias could 
not be ruled out as the funnel plot and Egger's test indicated the possibility 
of unpublished small studies with negative results for the use of BB. 
 
CONCLUSIONS 
The perioperative use of BB is effective in preventing POAF even in patients 
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TABLE 1. Study Characteristics 
 
RCT = randomized controlled study, NRS = non-randomized study, BB = beta-blocker, iCABG = isolated coronary artery bypass graft 
surgery, PSM = propensity score matching, MV = multivariable analysis. 
20 
 
*History of beta-blocker use was identified in 15431 of 15580 total study patients. 
†Possible proportion was estimated. 
‡Data were drawn from overall study population (n = 4076, BB group vs control = 2648 vs 1428)  
21 
 




 BB = beta-blocker, CHF = congestive heart failure, POAF = postoperative atrial fibrillation. 
*data from the entire group before matching  
23 
 






FIGURE 1. Flow diagram based on Preferred Reporting Items for 





FIGURE 2. Odd ratio (OR) of the occurrence rates of postoperative 
atrial fibrillation between patients with beta-blocker (BB) and those 





FIGURE 3. (A) Meta-regression analysis and (B) a forest plot 
demonstrated that proportions of patients who underwent surgery 
other than isolated coronary artery bypass grafting (iCABG) was not 
significantly associated with the odds ratio (OR) of postoperative atrial 






FIGURE 4. Subgroup analysis of odds ratio (OR) according to the 





FIGURE 5. (A) Pooled analysis of in-hospital mortality between 
patients with beta-blocker (BB) and those without BB showed a 
statistically significant difference. (B) However, the OR became 
insignificant when the result of 90-day mortality from one study (O’Neal 





FIGURE 6. Odds ratio (OR) of postoperative stroke in patients with 





FIGURE 7. Mean difference (MD) of length of hospital stay in patients 
with beta-blcocker (BB) and those without. (M = mean, SD = standard 
deviation, CI = confidence interval, RCT = randomized controlled trial, 






FIGURE 8. Odds ratio (OR) regarding (A) bradycardia, (B) hypotension 
and (C) a need of permanent pacemaker insertion in patients with beta-






FIGURE 9. Proportions of patients in whom beta-blocker (BB) dose 












심장수술환자에서 수술 전후 베타 차단제의 사용
이 수술 후 심방세동 발생에 미치는 영향에 대한 
메타분석 연구 




서론: 심방세동은 심장 수술 후 발생하는 가장 흔한 합병증 중 하나로 
수술 후 질병 이환율과 사망률을 유의하게 증가시킨다. 본 연구는 수술 
전후 베타 차단제 사용이 단독 관상동맥 우회로 수술 이외의 심장 수술 
후 발생하는 심방세동에 미치는 영향에 대하여 메타분석을 시행하고, 그 
임상적 의미를 도출하고자 한다.  
방법: 5개의 주요 온라인 문헌 데이터베이스를 검색하여 다음 두 가지 
기준에 적합한 연구들을 취합하였다. (1) 단독 관상동맥 우회로 수술 이
외의 심장 수술을 시행한 환자군을 대상으로 한 연구인 동시에 (2) 무
작위대조시험 혹은 보정분석을 바탕으로 수술 전후 베타 차단제의 사용
이 수술 후 발생하는 심방세동에 미치는 영향을 분석한 연구인 경우 본 
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연구 대상에 포함하였다. 심장 수술 후 심방세동의 발생율을 분석의 일
차 결과로 설정하였고, 단독 관상동맥 우회로 수술 외의 심장 수술 환자
의 비율 및 베타 차단제의 사용 시점을 근거로 각각 메타회귀분석 및 하
위집단 분석을 시행하였다.  
결과: 5개의 무작위 대조 연구 및 8개의 비무작위 연구를 포함하여 총 
13개의 문헌을 연구대상으로 선정하였다. 연구에 포함된 환자 중 단독 
관상동맥 우회로 수술 외의 심장 수술을 받은 환자의 비율은 7% 에서 
100%의 범주를 보였다. 베타 차단제는 5개의 연구에서 수술 전, 5개의 
연구에서 수술 후 혹은 수술 중, 나머지 3개의 연구에서는 수술 전후 모
든 시점에 사용되었다. 혼주 분석 결과, 수술 후 심방세동 발생의 위험
도는 수술 전후 베타 차단제를 사용한 군이 그렇지 않은 군에 비하여 유
의하게 낮았다 (odds ratio (OR), 95% confidence interval (CI) = 0.67, 
0.54-0.83). 하위집단 분석 결과, 단독 관상동맥 우회로 수술 외의 심
장 수술 환자의 비율 및 베타 차단제의 사용 시점은 수술 전후 베타 차
단제의 사용이 수술 후 심방세동의 발생 위험도를 낮추는데 유의한 영향
을 미치지 못하였다. 베타 차단제를 사용한 환자군에서 병원 내 사망률
은 유의하게 50 % 감소하였다 (OR, 95% CI = 0.50, 0.32-0.79). 수술 
전후 뇌졸중의 발생과 재원 기간은 베타 차단제를 사용한 군과 그렇지 
않은 군 사이에 유의한 차이를 보이지 않았다.  
결론: 수술 전후 베타 차단제의 사용은 심장 수술 후 발생하는 심방세동 
예방에 유의한 효과를 보인다. 
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